Cargando…
A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)
Autores principales: | Bensalem, A, Bouzid, K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231924/ http://dx.doi.org/10.1186/bcr1244 |
Ejemplares similares
-
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
por: Gampenrieder, Simon Peter, et al.
Publicado: (2021) -
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012) -
Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months
por: Noor, Ramadhani A, et al.
Publicado: (2010) -
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
por: Adamo, V, et al.
Publicado: (2008) -
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
por: Passardi, Alessandro, et al.
Publicado: (2006)